Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134678 | 1.00 | CYP2C9 (0.56) | CYP2C9GLO1ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL8007864 | 0.98 | CYP2C9 (0.55) | CYP2C9GLO1ALDH1A1LMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL28568635 | 0.96 | CYP2C9 (0.53) | CYP2C9GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3410835 | 0.88 | CYP2C9 (0.53) | CYP2C9GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3410836 | 0.88 | CYP2C9 (0.53) | CYP2C9GLO1ALDH1A1LMNAHSD17B10 | |
| Acrylamide SCHEMBL28108437 | 0.88 | CYP2C9 (0.46) | CYP2C9GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL524762 | 0.83 | CYP2C9 (0.41) | CYP2C9GLO1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16868400 | 0.83 | CYP2C9 (0.41) | CYP2C9GLO1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4059450 | 0.82 | CYP2C9 (0.43) | CYP2C9GLO1ALDH1A1LMNAHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28001098 | 0.82 | CYP2C9 (0.40) | CYP2C9GLO1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130209811-A1 | METHOD FOR DEPOSITING A BIOCIDAL COATING ON A SUBSTRATE | VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK (VITO) (BE) | 2013-08-15 | — | — | US | claimed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10173996-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-9908865-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908865-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9714230-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714230-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20130209811-A1 | METHOD FOR DEPOSITING A BIOCIDAL COATING ON A SUBSTRATE | VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK (VITO) (BE) | 2013-08-15 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-4460568-A | Quaternary, copolymeric, high molecular weight ammonium salts based on acrylic compounds, their preparation, and their use in cosmetics | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| US-4460567-A | HAIR TREATMENT, ACRYLAMIDE COPOLYMERS | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| US-4460569-A | SULFOSUCCINATE ANIONIC SURFACTANT | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| US-4460570-A | HAIR CONDITIONING, ACRYLAMIDE COPOLYMERS | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| US-4454114-A | Quaternary, copolymeric, high molecular weight ammonium salts based on acrylic compounds, and their use in cosmetics for the hair | CIBA-GEIGY CORPORATION (US) | 1984-06-12 | — | — | US | disclosed |
| US-4440744-A | Quaternary, copolymeric, high molecular weight ammonium salts based on acrylic compounds, and their use in cosmetics | CIBA-GEIGY CORPORATION (US) | 1984-04-03 | — | — | US | disclosed |
| US-4419344-A | Quaternary, copolymeric, high molecular weight ammonium salts based on acrylic compounds, their preparation, and their use in cosmetics | CIBA-GEIGY CORPORATION (US) | 1983-12-06 | — | — | US | disclosed |
| US-4393886-A | Mixtures of quaternary, polymeric, high molecular weight ammonium salts, which are based on acrylic compounds, and surfactants, their preparation, and their use in cosmetics | CIBA-GEIGY CORPORATION (US) | 1983-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10173996-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | CYP2C9 1544/4885GLO1 430/4885ALDH1A1 396/4885 |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | CYP2C9 1544/4885GLO1 430/4885ALDH1A1 396/4885 |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CYP2C9 559/4885GLO1 3795/4885ALDH1A1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.